The formation of platelet-leukocyte aggregates varies during the menstrual cycle

被引:21
作者
Rosin, C
Brunner, M
Lehr, S
Quehenberger, P
Panzer, S
机构
[1] Med Univ Vienna, Clin Blood Grp Serol, A-1090 Vienna, Austria
[2] Med Univ Vienna, Clin Med & Chem Lab Diagnost, A-1090 Vienna, Austria
[3] Med Univ Vienna, Core Unit Med Stat & Informat Clin Biometr, A-1090 Vienna, Austria
关键词
menstrual cycle; platelet-leukocyte aggregates; P-selectin; PAC-1;
D O I
10.1080/09537100500227021
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Platelet-leukocyte aggregates are considered to play a significant role in blood coagulation and inflammatory processes. We hypothesized that hormonal changes during the menstrual cycle affect the formation of heterotypic aggregates and therefore may constitute cycle-dependent variations of the susceptibility for thromboembolic events and inflammatory disease. We therefore measured platelet-leukocyte interaction by the determination of platelet-leukocyte aggregates (PLA), platelet P-Selectin expression, and platelet fibrinogen receptor activation by PAC-1 binding in 20 healthy women during their menstrual cycle by flow cytometry. The number of platelet-granulocyte aggregates (PGA) and platelet-monocyte aggregates (PMA) was higher at ovulation compared to any other time-point of the menstrual cycle (p = 0.005, p = 0.022, respectively). Likewise, P-Selectin expression peaked on day 14 (p = 0.040). The course of PLA formation during the menstrual cycle followed the course of estrogen levels, strongly suggesting direct effects of estrogen on platelet-leukocyte interaction. The susceptibility to form platelet-leukocyte aggregates that are inducible in vitro by a suboptimal concentration of thrombin receptor activating peptide-6 decreased slightly during the transition from day 1 to 14 (p = 0.040). These data indicate that platelet function varies during particular phases of the normal menstrual cycle.
引用
收藏
页码:61 / 66
页数:6
相关论文
共 30 条
[1]  
Boudoulas KD, 2001, ARCH PATHOL LAB MED, V125, P112
[2]  
Faraday N, 1997, THROMB HAEMOSTASIS, V77, P748
[3]   Alterations in platelet function during the ovarian cycle [J].
Feuring, A ;
Christ, A ;
Roell, A ;
Schueller, P ;
Losel, R ;
Dempfle, CE ;
Schultz, A ;
Wehling, M .
BLOOD COAGULATION & FIBRINOLYSIS, 2002, 13 (05) :443-447
[4]   Platelet-monocyte aggregates - Bridging thrombosis and inflammation [J].
Freedman, JE ;
Loscalzo, J .
CIRCULATION, 2002, 105 (18) :2130-2132
[5]   Cardiovascular disease outcomes during 6.8 years of hormone therapy - Heart and Estrogen/progestin Replacement Study follow-up (HERS II) [J].
Grady, D ;
Herrington, D ;
Bittner, V ;
Blumenthal, R ;
Davidson, M ;
Hlatky, M ;
Hsia, J ;
Hulley, S ;
Herd, A ;
Khan, S ;
Newby, LK ;
Waters, D ;
Vittinghoff, E ;
Wenger, N .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (01) :49-57
[6]   Human platelets contain estrogen receptor α, caveolin-1 and estrogen receptor associated proteins [J].
Jayachandran, M ;
Miller, VM .
PLATELETS, 2003, 14 (02) :75-81
[7]   Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count [J].
Jensen, MK ;
Brown, PD ;
Lund, BV ;
Nielsen, OJ ;
Hasselbalch, HC .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2001, 66 (03) :143-151
[8]   Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis [J].
Joseph, JE ;
Harrison, P ;
Mackie, IJ ;
Isenberg, DA ;
Machin, SJ .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (02) :451-459
[9]  
Kadir RA, 1999, THROMB HAEMOSTASIS, V82, P1456
[10]   Sex hormones and systemic lupus erythematosus [J].
Lahita, RG .
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2000, 26 (04) :951-+